CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GDTC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.01M
- EPS (TTM)
- -$0.23
- Dividend yield
- None
- 52-week range
- 0.68 – 2.12
- Day range
- 0.7131 – 0.7848
- Volume / Avg
- 15.48K / 15.69K
- Beta
- —
- Shares outstanding
- 11.93M
52-week range
GDTC stock today
On Nov 20, GDTC ended the session at $0.755, shedding $0.018 (2.33%), versus the S&P 500's 3.70% decline. At this level, GDTC sits near the bottom of its 52-week range of $0.68 to $2.12: 64.4% below the high, set on Dec 8, 2025 and 11.0% above the low. GDTC is down 43.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 59.8%.
CytoMed Therapeutics has posted a net loss over the last twelve months (EPS of -$0.23), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CytoMed Therapeutics
Company profileCytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Headquarters
- Singapore
- Employees
- 42
- IPO year
- 2023
- Website
- w2.cytomed.sg
Financial highlights
Full financialsIn fiscal 2025, CytoMed Therapeutics generated $252,265 in revenue, up 395.9% from fiscal 2024. CytoMed Therapeutics reported a net loss of $3.1 million, compared with a loss of $1.8 million a year earlier. Diluted earnings per share came in at -$0.27.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $252.26K | $50.87K | — | — |
| Growth | +395.88% | — | — | — |
| Net income | $-3.10M | $-1.84M | $-3.13M | $-2.34M |
| EPS (diluted) | $-0.27 | $-0.16 | $-0.29 | $-0.30 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$4.16+450.99%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
GDTC news
All GDTC newsCytoMed Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BFRIBiofrontera Inc. | 0.53 | -7.02% | $9.51M | vs GDTC |
| CMMBChemomab Therapeutics Ltd. ADR | 1.19 | +4.39% | $9.58M | vs GDTC |
| CALCCalciMedica Inc. | 1.26 | +7.69% | $8.69M | vs GDTC |
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs GDTC |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs GDTC |
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs GDTC |
| HINDVyome Holdings Inc. | 1.20 | -17.24% | $8.42M | vs GDTC |
| RADXRadiopharm Theranostics Limited ADR | 0.6304 | -9.71% | $9.90M | vs GDTC |
Indexes, lists and sector
CytoMed Therapeutics stock FAQ
What is CytoMed Therapeutics's stock price today?
GDTC last traded at $0.755 as of Nov 20, 4:00 PM EST, down 2.33% on the day. Prices are delayed at least 15 minutes.
What is the GDTC 52-week high?
The 52-week high for GDTC is $2.12 and the 52-week low is $0.68. The stock is currently 64.4% below its high.